Advertisement
Advertisement
RLAY
Relay Therapeutics, Inc. Common Stock
10.60
USDSponsored
-0.09
-0.89%
Mar 11, 11:54 UTC -4
Open
RLAY Earnings Reports
Positive Surprise Ratio
RLAY beat 14 of 23 last estimates.
61%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q1 26 (Revenue/ EPS)
$102.00K
/-$0.39
Implied change from Q4 25 (Revenue/ EPS)
-98.54%
/+21.88%
Implied change from Q1 25 (Revenue/ EPS)
-98.67%
/-15.22%
Relay Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, RLAY reported earnings of -0.32 USD per share (EPS) for Q4 25, beating the estimate of -0.41 USD, resulting in a 22.41% surprise. Revenue reached 7.00 million, compared to an expected 5.06 million, with a 38.21% difference. The market reacted with a -1.81% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 102.00 thousand USD, implying an increase of 21.88% EPS, and decrease of -98.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.45
Actual
-$0.42
Surprise
+6.77%
Esperion Therapeutics, Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.24
Actual
$0.22
Surprise
-10.46%
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
Zevra Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
$0.05
Actual
$0.21
Surprise
+311.76%
SIGA Technologies Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
-Actual
-$0.08
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.19
Actual
$0.30
Surprise
+54.80%
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.51
Surprise
+37.05%
PMV Pharmaceuticals, Inc
Report Date
Mar 06, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.34
Surprise
+17.70%
FAQ
What were Relay Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Relay Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 22.41%, and revenue of $7.00M, 38.21% above expectations.
How did the market react to Relay Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -1.81%, changed from $8.86 before the earnings release to $8.70 the day after.
When is Relay Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Relay Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Relay Therapeutics, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $102.00K for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement